Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates
- PMID: 22201473
- PMCID: PMC3327605
- DOI: 10.1089/hum.2011.200
Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates
Abstract
Widespread distribution of gene products at clinically relevant levels throughout the CNS has been challenging. Adeno-associated virus type 9 (AAV9) vector has been reported as a good candidate for intravascular gene delivery, but low levels of preexisting antibody titers against AAV in the blood abrogate cellular transduction within the CNS. In the present study we compared the effectiveness of vascular delivery and cerebrospinal fluid (CSF) delivery of AAV9 in transducing CNS tissue in nonhuman primates. Both delivery routes generated similar distribution patterns, although we observed a more robust level of transduction after CSF delivery. Consistent with previous reports administering AAV9, we found greater astrocytic than neuronal tropism via both routes, although we did find a greater magnitude of CNS transduction after CSF delivery compared with intravascular delivery. Last, we have demonstrated that delivery of AAV9 into the CSF does not shield against AAV antibodies. This has obvious implications when developing and/or implementing any clinical trial studies.
Figures





Comment in
-
Challenges for gene therapy of CNS disorders and implications for Parkinson's disease therapies.Hum Gene Ther. 2012 Apr;23(4):340-3. doi: 10.1089/hum.2012.2507. Epub 2012 Apr 10. Hum Gene Ther. 2012. PMID: 22490128 No abstract available.
Similar articles
-
Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates.Hum Gene Ther. 2013 May;24(5):526-32. doi: 10.1089/hum.2013.005. Epub 2013 May 2. Hum Gene Ther. 2013. PMID: 23517473 Free PMC article.
-
AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.Mol Ther. 2019 Nov 6;27(11):2018-2037. doi: 10.1016/j.ymthe.2019.07.017. Epub 2019 Aug 5. Mol Ther. 2019. PMID: 31420242 Free PMC article.
-
Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.Gene Ther. 2013 Apr;20(4):450-9. doi: 10.1038/gt.2012.101. Epub 2013 Jan 10. Gene Ther. 2013. PMID: 23303281 Free PMC article.
-
Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.Brain Res. 2020 Jul 15;1739:146832. doi: 10.1016/j.brainres.2020.146832. Epub 2020 Apr 11. Brain Res. 2020. PMID: 32289279 Free PMC article. Review.
-
Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.J Control Release. 2016 Nov 10;241:94-109. doi: 10.1016/j.jconrel.2016.09.011. Epub 2016 Sep 13. J Control Release. 2016. PMID: 27637390 Review.
Cited by
-
Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates.Hum Gene Ther. 2013 May;24(5):526-32. doi: 10.1089/hum.2013.005. Epub 2013 May 2. Hum Gene Ther. 2013. PMID: 23517473 Free PMC article.
-
Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy.J Neuromuscul Dis. 2021;8(1):25-38. doi: 10.3233/JND-200531. J Neuromuscul Dis. 2021. PMID: 33074186 Free PMC article. Review.
-
In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside.PLoS One. 2013;8(3):e57908. doi: 10.1371/journal.pone.0057908. Epub 2013 Mar 4. PLoS One. 2013. PMID: 23483939 Free PMC article.
-
Design and Validation of a Multi-Point Injection Technology for MR-Guided Convection Enhanced Delivery in the Brain.Front Med Technol. 2021 Oct 14;3:725844. doi: 10.3389/fmedt.2021.725844. eCollection 2021. Front Med Technol. 2021. PMID: 35047955 Free PMC article.
-
Adeno-associated virus serotypes 9 and rh10 mediate strong neuronal transduction of the dog brain.Gene Ther. 2014 Jan;21(1):28-36. doi: 10.1038/gt.2013.54. Epub 2013 Oct 17. Gene Ther. 2014. PMID: 24131981 Free PMC article.
References
-
- Boutin S. Monteilhet V. Veron P., et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum. Gene Ther. 2010;21:704–712. - PubMed
-
- Chirmule N. Propert K. Magosin S., et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999;6:1574–1583. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources